023910.KQ
Strong BuyUnloved QualityAI neutralDaihan Pharmaceutical Co.,Ltd. · Healthcare · South Korea · $114M
KRW 26,100 -0.9% · close 2 Oct · scored 6 Oct
Unloved Quality: Strong and cheap; the market has not turned yet.
Does StockRank work? Each month we publish how every decile did, whichever way it went. See the record →
Daihan Pharmaceutical is a Korean maker of intravenous fluids and basic hospital pharmaceuticals, a stable domestic business with a strong market share and small recent insider buying. Pricing is largely set by Korea's national health insurance, so growth is modest and there is no clear catalyst.
ABOUT DAIHAN PHARMACEUTICAL CO.,LTD.
Read
Daihan Pharmaceutical Co.,Ltd. is a prominent South Korean pharmaceutical company specializing in the development, manufacturing, and distribution of intravenous solutions, nutritional products, and various specialized drugs. The company holds a leading market position in the domestic intravenous fluid segment, leveraging advanced manufacturing capabilities and extensive distribution networks to hospitals and clinics. Its competitive moat is reinforced by strict regulatory requirements and a focus on essential medical supplies.
FINANCIAL SUMMARY (KRW)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 184.3B | 195.9B | 204.2B | 208.6B | 4.2% | 216.8B | 222.0B | 232.5B | 5.6% |
| EPS (KRW) | — | 4,171 | 4,834 | 5,741 | 4,701 | 4.1% | 4,706 | 4,611 | 4,885 | 1.9% |
| Shares | — | 5.9M | 5.9M | 5.9M | 5.9M | 0.0% | 5.9M | — | — | — |
| Debt | 23.5B | 6.5B | — | 29.0M | 13.3M | -84.6% | 48.0M | — | — | — |
| Equity | — | 225.4B | 248.0B | 276.0B | 300.2B | 10.0% | — | — | — | — |
| Op CF | — | 29.0B | 38.9B | 35.6B | 25.6B | -4.1% | 37.4B | — | — | — |
| Inv CF | — | 193.5M | -18.0B | -72.6B | -37.6B | — | — | — | — | — |
| Fin CF | — | -22.5B | -10.3B | -4.4B | -5.2B | — | — | — | — | — |
Calmer than 88% of stocks we rank over the past year (22% a year).
How this is worked out
What it measures: day-to-day price moves over the past year, as a yearly figure, ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 023910.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 023910.KQ | Daihan Pharmaceutical Co.,Ltd.(you) | $114M | 90 | Strong Buy |
| 234080.KS | JW Lifescience Corporation | $126M | 94 | Strong Buy |
| 001630.KS | Chong Kun Dang Holdings Corp. | $132M | 86 | Strong Buy |
| 016580.KS | Whan In Pharm Co.,Ltd. | $137M | 94 | Strong Buy |
| 005500.KS | Samjin Pharmaceuticals Co., Ltd. | $172M | 90 | Strong Buy |
| 033270.KS | Korea United Pharm Inc. | $206M | 87 | Strong Buy |
| 008490.KS | Suheung Co., Ltd. | $163M | 82 | Strong Buy |
| 001540.KQ | Ahn-Gook Pharmaceutical Co., Ltd. | $84M | 100 | Strong Buy |
| 106190.KQ | High Tech Pharm Co., Ltd. | $78M | 80 | Strong Buy |
| 002800.KQ | Sinsin Pharmaceutical Co., Ltd | $51M | 93 | Strong Buy |
Peer medians: ROE -0.3% · P/E 17.6x · Gross margin 43.2%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.